Chronic Obstructive Pulmonary Disease (COPD) Clinical Trial
— NEUROTIGUEOfficial title:
Towards a Better Understanding of Neuromuscular Alterations and Fatigue in Chronic Obstructive Pulmonary Disease (COPD)
Verified date | March 2024 |
Source | Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Fatigue is a prevalent symptom in Chronic Obstructive Pulmonary Disease (COPD) that limits patients in their daily living activities. It is now well established that COPD patients may have altered neuromuscular functions compared to healthy individuals. However, the different studies conducted on muscle fatigue in COPD have been done independently of any cognitive solicitation, yet present in most of daily living activities. Therefore, the aim of this research is to evaluate the impact of the disease on neuromuscular fatigue during dual-task situation (simultaneous accomplishment of a muscle contraction and a cognitive task). A better understanding of fatigue in COPD will promote the development of new perspectives in patient management. The hypothesis is that COPD patients will exhibit increased fatigue level (compared to healthy subjects), particularly during dual-task situation. It is assumed that the higher negative effect associated with the dual-task will be related to different neurophysiological mechanisms (i.e., neuromuscular fatigue, autonomic nervous system activity, mental fatigue).
Status | Completed |
Enrollment | 36 |
Est. completion date | February 17, 2023 |
Est. primary completion date | February 17, 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 40 Years and older |
Eligibility | Inclusion Criteria: COPD patients : - GOLD II - III or IV - FEV1 <80% of predicted values - Men and women aged 40 years and over - French-speaking participant - BMI <30 kg / m² - Stable condition (i.e. without exacerbation) for more than 15 days - Able to express their consent in writing prior to any participation in the study - Affiliates or beneficiaries of a social security - Minimum score of 26 on the MMSE questionnaire of 3 months or less Healthy volunteers : - Men and women aged 40 years and over - French-speaking participant - BMI <30 kg / m² - No known chronic respiratory, cardiovascular, metabolic, renal or neuromuscular pathologies - Able to express their consent in writing prior to any participation in the study - Affiliates or beneficiaries of a social security - Minimum score of 26 on the MMSE questionnaire of 3 months or less Exclusion Criteria: COPD patients : - Alcoholism, i.e. > 21 glasses a week for men and >14 glasses a week for women - Psychiatric pathologies or antecedent of behavioral disorders - Patients treated with oral or systemic corticosteroids (> 0.5 mg / kg / day for > 7 days) - Contraindication to the application of a magnetic field (i.e. right hip arthroplasty, pelvic / abdominal surgeries) - Severe vision or hearing problems not corrected - Patient oxygen dependent - Patients in exclusion period from another research protocol - Pregnant women (known pregnancy) or lactating women - Patient deprived of liberty by a judicial or administrative decision - Patient subject to a legal protection measure or unable to express their consent - Patient who is not sufficiently fluent in reading and understanding the French language to be able to consent to participate in the study - Patient unable to follow study procedures and to respect visits throughout the study period - Person with a medical history that, in the opinion of the investigator, could interfere with the results of the study - Any condition that, in the opinion of the investigator, could increase and compromise the safety of the person in the event that he / she participates in the study - Any other reason that, in the opinion of the investigator, could interfere with the evaluation of the aims of the study Healthy volunteers: - Alcoholism, i.e. > 21 glasses a week for men and >14 glasses a week for women - Psychiatric pathologies or antecedent of behavioral disorders - Patients treated with oral or systemic corticosteroids (> 0.5 mg / kg / day for > 7 days) - Contraindication to the application of a magnetic field (i.e. right hip arthroplasty, pelvic / abdominal surgeries) - Severe vision or hearing problems not corrected - Subjects in exclusion period from another research protocol - Pregnant women (known pregnancy) or lactating women - Regular physical activity with a frequency greater than 3 sessions per week - Participant deprived of liberty by a judicial or administrative decision - Participant subject to a legal protection measure or unable to express their consent - Participant who is not sufficiently fluent in reading and understanding the French language to be able to consent to participate in the study - Participant unable to follow study procedures and to respect visits throughout the study period - Person with a medical history that, in the opinion of the investigator, could interfere with the results of the study - Any condition that, in the opinion of the investigator, could increase and compromise the safety of the person in the event that he / she participates in the study - Any other reason that, in the opinion of the investigator, could interfere with the evaluation of the aims of the study |
Country | Name | City | State |
---|---|---|---|
France | Université de Toulon, laboratoires LAMHESS et IAPS | La Garde | Var |
France | Hôpital d'Instruction des Armées Sainte-Anne | Toulon | Var |
Lead Sponsor | Collaborator |
---|---|
Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer | Université de Toulon |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Endurance time differences between simple and dual-task conditions, in COPD patients compared to healthy participants | The endurance times will correspond to the duration of the fatiguing tasks (simple and dual-task). The endurance time differences between simple and dual-task conditions will be calculated as follows : Endurance time in simple task condition - Endurance time in dual-task condition = Difference of endurance time. | 7 days | |
Secondary | Neuromuscular fatigue of knee extensors | The neuromuscular fatigue will be evaluated regularly during the fatiguing tasks using the magnetic stimulation of the femoral nerve , during and after maximal voluntary contraction. Moreover, the muscle activity of the Vastus Lateralis, using non-invasive surface electromyography (sEMG), will be continuously recorded during the fatiguing tasks. | About each minute during the fatiguing tasks lasting about 20 minutes | |
Secondary | Autonomic nervous system activity | Autonomic nervous system activity will be continuously recorded during the fatiguing tasks using cardiac measurements . | Continuously during the fatiguing tasks lasting about 20 minutes | |
Secondary | Mental fatigue | The influence of mental fatigue on the performance will be assessed using the cognitive performance (i.e. rate of correct answers and reaction time) that will be continuously recorded during fatiguing dual-task. | Continuously during the fatiguing task in dual-task condition, which should last about 20 minutes | |
Secondary | Psychological state | Psychology influence on task performance will be evaluated with questionnaires before, during and after the task. For motivation: 14 items, scores from 0 (not at all) to 4 (extremely), 2 subscales assessing intrinsic and success-based motivation (scores from 0 to 28). For mood: 24 adjectives, scores from 0 (not at all) to 4 (extremely), 6 subscales evaluating fatigue, confusion, vigor, depression, tension and anger (scores from 0 to 16). For Rating-of-Fatigue scale: one score from 0 (not tired) to 10 (exhaustion). For dyspnea: one score from 0 (nothing) to 10 (extremely strong). For Task Load Index: 6 subscales, from 0 (very low) to 20 (very high), measure mental and physical difficulties, time pressure, performance perception, effort perception and frustration. For Sleep Quality Index: 24 questions, 7 subscales from 0 to 3 evaluating subjective sleep quality, sleep latency, sleep duration, sleep efficiency, sleep disturbance, sleep medication and day dysfunction due to sleepiness. | Before, during and after fatiguing task lasting about 20 minutes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03282019 -
Study of Long-term HFNC for COPD Patients With HOT
|
N/A | |
Completed |
NCT05573464 -
A Study to Assess the Safety of Budesonide/Glycopyrronium/Formoterol Fumarate With the Hydrofluoroolefin Propellant in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
|
Phase 3 | |
Recruiting |
NCT06040086 -
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations
|
Phase 3 | |
Not yet recruiting |
NCT06376994 -
Multi-Center Clean Air Randomized Controlled Trial in COPD
|
Phase 3 | |
Completed |
NCT02728674 -
Management of Patients With Respiratory Symptoms in Sweden
|
N/A | |
Completed |
NCT02797392 -
Feasibility of a Preventive Program Against Lifestyle Related Diseases
|
N/A | |
Completed |
NCT02926534 -
Cross-Sectional Study of COPD Prevalence Among Smokers, Ex-smokers and Never-Smokers in Almaty, Kazakhstan
|
N/A | |
Recruiting |
NCT02415478 -
Bronchioscopic Lung Volume Reduction (BLVR)
|
N/A | |
Completed |
NCT02774226 -
Long Term Nitric Oxide Bioavailability on Vascular Health in Chronic Obstructive Pulmonary Disease
|
Phase 2 | |
Completed |
NCT03487406 -
Anti-platelet Therapy in the Prevention of Cardiovascular Disease in Patients With COPD (APPLE-COPD: ICON 2)
|
Phase 2 | |
Completed |
NCT02512510 -
Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Completed |
NCT02459080 -
Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Completed |
NCT02518139 -
A 52-Week Parallel Group Safety Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Completed |
NCT01908140 -
Study of Aclidinium Bromide/Formoterol Fumarate Compared With Salmeterol/Fluticasone Propionate in Patients With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Withdrawn |
NCT01908933 -
Study of the AeriSeal System Treatment in Patients With Advanced Non-Upper Lobe Predominant Heterogeneous Emphysema
|
Phase 3 | |
Completed |
NCT01893476 -
A Pragmatic Cluster Trial of a Tailored Intervention to Improve COPD Management
|
N/A | |
Completed |
NCT01615484 -
Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability
|
N/A | |
Completed |
NCT01701869 -
Microbiology & Immunology of the Chronically-inflamed Airway
|
N/A | |
Recruiting |
NCT02527486 -
Seoul National University Airway Registry
|
N/A | |
Withdrawn |
NCT01377428 -
Efficacy of Indacaterol 150 µg Versus Formoterol
|
Phase 4 |